Lexeo Therapeutics
LXEO · Nasdaq · United States
Share price · LXEO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LXEO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-11.6%
- 16 Nov 2026+12.5%
- 28 Oct 2026+9.1%
Nothing announced by LXEO that day or the session before.
- 13 Oct 2026-9.9%
Nothing announced by LXEO that day or the session before.
- 1 Oct 2026+7.1%
- 29 Sep 2026+8.9%
- 28 Sep 2026-5.1%
Nothing announced by LXEO that day or the session before.
- 23 Sep 2026-13.5%
- 8 Jul 2026+10.2%
Nothing announced by LXEO that day or the session before.
- 20 May 2026+14.3%
Share of unusual movement by asset
For each asset, the share of LXEO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
LX1001events and moves | 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 38% |
| Sessions with no dated event | — | 60% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | APOE2 (gene therapy)Gene therapy / editing | Alzheimer's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (12)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $19M | $96M+ $119M short-term inv. | $26M-$18M operating cash flow | report ↗ |
View 11 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $16M | $75M+ $121M short-term inv. | $20M-$21M operating cash flow | report ↗ |
| 2025-Q3 | — | $16M | $44M+ $82M short-term inv. | $20M-$30M operating cash flow | report ↗ |
| 2025-Q2 | — | $15M | $39M+ $97M short-term inv. | $26M-$27M operating cash flow | report ↗ |
| 2025-Q1 | — | $17M | $32M+ $71M short-term inv. | $33M-$22M operating cash flow | report ↗ |
| 2024-Q3 | — | $23M | $160M | $29M-$18M operating cash flow | report ↗ |
| 2024-Q2 | — | $17M | $178M | $21M-$20M operating cash flow | report ↗ |
| 2024-Q1 | — | $16M | $198M | $22M-$15M operating cash flow | report ↗ |
| 2023-Q3 | — | $17M | $39M | $20M-$14M operating cash flow | report ↗ |
| 2023-Q2 | — | $11M | $49M | $13M-$13M operating cash flow | report ↗ |
| 2023-Q1 | — | $16M | $62M | $19M-$18M operating cash flow | report ↗ |
| 2022-Q3 | $0.5M | $15M | $97M | $17M | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $64M | $66M+ $119M short-term inv. | $25M-$99M operating cash flow | report ↗ |
Lexeo Therapeutics reported no revenue for FY2025. R&D spend was $63.8M, down 13.9% YoY, and cash and equivalents were $66.25M, while cash, cash equivalents and investments totaled $246.6M at year-end. The annual net loss was $99.96M, or $1.86 per share.
Management said the $246.6M cash position is expected to fund operations into 2028. The company submitted the SUNRISE-FA 2 pivotal trial protocol and SAP for LX2006 to the FDA in Q1 2026 after a Type B meeting, with study initiation on track for 1H 2026, held an initial CMC Development and Readiness Program meeting, and presented continued positive interim data for LX2006 and LX2020 at the ACC Annual Meeting. It also established a research collaboration with Johnson & Johnson for targeted cardiac delivery of AAV gene therapy, executed a $154M equity financing in October 2025, and added a new Chief Medical Officer and senior cardiac leadership.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 15 sales ($739K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Townsend Richard Nolan · director, Chief Executive Officer | Open-market sale | 3,295 | $3.26 | $11K | Form 4 |
| 2026-11-17 | Otero Jose Manuel · Chief Operating Officer | Open-market sale | 1,285 | $3.26 | $4K | Form 4 |
| 2026-11-17 | Tamayo Louis Edward · Chief Financial Officer | Open-market sale | 1,007 | $3.26 | $3K | Form 4 |
| 2026-11-14 | Schilke Tobin · director | Award / grant (derivative) | 70,000 | — | — | Form 4 |
| 2026-09-24 | Tamayo Louis Edward · Chief Financial Officer | Award / grant (derivative) | 54,750 | — | — | Form 4 |
| 2026-09-24 | Townsend Richard Nolan · director, Chief Executive Officer | Award / grant (derivative) | 145,500 | — | — | Form 4 |
| 2026-09-24 | Otero Jose Manuel · Chief Operating Officer | Award / grant (derivative) | 54,750 | — | — | Form 4 |
| 2026-09-24 | Bhalla Narinder Pal · Chief Medical Officer | Award / grant (derivative) | 54,750 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 138 reporting institutions held 79.9M shares ($458.2M, 101.7% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 6,184,134 | $35.5M |
| 2 | BlackRock, Inc. | 5,110,871 | $29.3M |
| 3 | Affinity Asset Advisors, LLC | 5,050,211 | $29.0M |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 5,000,000 | $28.7M |
| 5 | JANUS HENDERSON GROUP PLC | 4,976,429 | $28.5M |
| 6 | Vestal Point Capital, LP | 4,475,000 | $25.7M |
| 7 | Frazier Life Sciences Management, L.P. | 4,424,725 | $25.4M |
| 8 | CITADEL ADVISORS LLC | 3,834,999 | $22.0M |
| 9 | ORBIMED ADVISORS LLC | 3,602,450 | $20.7M |
| 10 | STATE STREET CORP | 3,568,242 | $20.5M |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 3,007,093 | $17.3M |
| 12 | Woodline Partners LP | 2,750,532 | $15.8M |
| 13 | GOLDMAN SACHS GROUP INC | 1,949,885 | $11.2M |
| 14 | Avoro Capital Advisors LLC | 1,875,000 | $10.8M |
| 15 | Point72 Asset Management, L.P. | 1,680,449 | $9.6M |